AIM ImmunoTech Inc. (AIM) Financial Statements (2025 and earlier)

Company Profile

Business Address 2117 SW HIGHWAY 484
OCALA, FL 32801
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13,07034,19048,26838,5011,470299
Cash and cash equivalent5,43927,05332,09338,5011,470299
Short-term investments7,6317,13716,175   
Receivables 1,1841,6761,6411,1248201,094
Other undisclosed current assets3024553046858,1562,406
Total current assets:14,55636,32150,21340,31010,4463,799
Noncurrent Assets
Operating lease, right-of-use asset697829149179152
Property, plant and equipment1271954,0476,4737,1167,782
Intangible assets, net (including goodwill)2,3131,9411,9741,4981,151912
Intangible assets, net (excluding goodwill)2,3131,9411,9741,4981,151912
Other noncurrent assets1,6881,2021,3167481,3541,352
Other undisclosed noncurrent assets    15,376  
Total noncurrent assets:4,8254,1677,48624,2749,77310,046
TOTAL ASSETS:19,38140,48857,69964,58420,21913,845
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8,4291,1836368258751,685
Accounts payable6,443377198383472680
Accrued liabilities1,9868064384424031,005
Debt   230252 
Other undisclosed current liabilities2231783747 3,607
Total current liabilities:8,6521,3616731,1021,1275,292
Noncurrent Liabilities
Long-term debt and lease obligation   1122,0082,2182,318
Long-term debt, excluding current maturities    1,8762,1042,318
Liabilities, other than long-term debt495659    
Operating lease, liability495659112132114
Total noncurrent liabilities:4956592242,1402,2182,318
Total liabilities:9,1472,0208973,2423,3457,610
Equity
Equity, attributable to parent, including:10,23438,46856,87961,29412,9075,174
Preferred stock  696715732  
Common stock494848421049
Additional paid in capital419,004418,270417,217402,541340,228323,701
Accumulated other comprehensive loss    (47) (3)
Accumulated deficit(409,508)(380,546)(361,101)(341,974)(328,109)(318,573)
Other undisclosed equity, attributable to parent 689   778 
Total equity:10,23438,46856,87961,29412,9075,174
Other undisclosed liabilities and equity   (77)483,9671,061
TOTAL LIABILITIES AND EQUITY:19,38140,48857,69964,58420,21913,845

Income Statement (P&L) ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues202141135163140367
Loss on disposition of assets for financial service operations(176)(751)    
Cost of revenue(42) (950)(941)(2,023)(1,517)
Cost of product and service sold(42) (850)(806)(893)(884)
Gross profit:160141(815)(778)(1,883)(1,150)
Operating expenses(32,076)(20,064)(18,023)(14,374)(10,560)(10,346)
Operating loss:(31,916)(19,923)(18,838)(15,152)(12,443)(11,496)
Nonoperating income (expense)1,269(1,050)(201)   
Investment income, nonoperating200(1,679)(201)   
Other nonoperating income1,069629    
Interest and debt expense   (2,768)(530)(427)(502)
Loss from continuing operations:(30,647)(20,973)(21,807)(15,682)(12,870)(11,998)
Loss before gain (loss) on sale of properties:(21,807)(15,682)(12,870)(11,998)
Net loss:(30,647)(20,973)(21,807)(15,682)(12,870)(11,998)
Other undisclosed net income (loss) attributable to parent1,6851,5282,6801,2823,3372,185
Net loss available to common stockholders, diluted:(28,962)(19,445)(19,127)(14,400)(9,533)(9,813)

Comprehensive Income ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(30,647)(20,973)(21,807)(15,682)(12,870)(11,998)
Comprehensive loss:(30,647)(20,973)(21,807)(15,682)(12,870)(11,998)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1,6851,5282,7271,2353,3372,171
Comprehensive loss, net of tax, attributable to parent:(28,962)(19,445)(19,080)(14,447)(9,533)(9,827)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: